Accordingly, the present study seeks to explore the association between early initiation of GLP-1 RA therapy—defined as within three months of T2DM diagnosis—and the subsequent risk of developing cancer, with particular focus on site-specific malignancies potentially influenced by GLP-1 receptor signaling. This evidence concerns the gene GCG and cancer.